Genmab A/S (FRA:GE91)
Germany
· Delayed Price · Currency is EUR 27.40
+0.40 (1.48%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Denmark Revenue | - | 2.75B |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue | - | 125.29M |
Log In |
Log In |
Log In | Upgrade
|
| Japan Revenue | - | 116.82M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 22.16B | 18.54B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 22.16B | 21.53B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| DARZALEX Royalties Revenue | 2.17B | 1.93B |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties Revenue | 369.13M | 308.65M |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties Revenue | 99.87M | 102.37M |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties Revenue | 80.75M | 65.42M |
Log In |
Log In |
Log In | Upgrade
|
| Total Royalties Revenue | 2.72B | 2.41B |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement Revenue | 95.31M | 138.35M |
Log In |
Log In |
Log In | Upgrade
|
| Milestone Revenue | 104.26M | 138.90M |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Revenue | 68.53M | 60.15M |
Log In |
Log In |
Log In | Upgrade
|
| License Revenue | - | 277.81K |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales | 313.38M | 242.11M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 16.13B | 16.13B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 22.16B | 21.53B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| J&J Revenue | 2.26B | 2.00B |
Log In |
Log In |
Log In | Upgrade
|
| Roche Revenue | 101.42M | 102.93M |
Log In |
Log In |
Log In | Upgrade
|
| Novartis Revenue | 453.22M | 391.99M |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech Revenue | 80.01M | 120.71M |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer Revenue | 79.48M | 74.04M |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie Revenue | 12.44M | 54.73M |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner Revenue | 2.28M | 277.81K |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 22.16B | 21.53B |
Log In |
Log In |
Log In | Upgrade
|